Table 3.
Results for Month 6.5 Immune Response Interaction Analyses of Per-Protocol Vaccine Recipients
| Variable, Continuous | IgG A244 V1V2, Categorical | HR Scale for Continuous Variable | HR (95% CI) | Unadjusted P | Adjusted P |
|---|---|---|---|---|---|
| CD4+ PFS ZM96 | Low | Per 1-SD | 2.20 (1.20–4.04) | ||
| Medium | Per 1-SD | 0.84 (.41–1.74) | <.0001 | .0017 | |
| High | Per 1-SD | 0.40 (.26–.63) | |||
| CD4+ PFS 1086 | Low | Per 1-SD | 3.59 (1.99–6.46) | ||
| Medium | Per 1-SD | 1.06 (.55–2.04) | <.0001 | .0002 | |
| High | Per 1-SD | 0.42 (.23–.76) | |||
| CD4+ PFS TV1 | Low | Per 1-SD | 2.30 (1.36–3.89) | ||
| Medium | Per 1-SD | 0.83 (.41–1.71) | .0016 | .033 | |
| High | Per 1-SD | 0.52 (.24–1.12) | |||
| CD4+ IFNg+/IL2+/CD40L+ ZM96 | Low | Per 1-SD | 3.20 (1.84–5.56) | ||
| Medium | Per 1-SD | 1.10 (.64–1.90) | <.0001 | .0001 | |
| High | Per 1-SD | 0.49 (.28–0.85) |
Cox proportional hazards regression results are shown for the models with significant interactions. Each model included 1 interaction term and associated main effects, adjusted for the baseline covariates age (≤25, >25 years) and a previously derived categorical HIV risk score for women.
Abbreviations: CI, confidence interval; HR, hazard ratio.